Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by SanFrancisco99on Apr 21, 2015 5:52pm
253 Views
Post# 23650377

Target Price of 3.25

Target Price of 3.25Yes, I'm not thrilled either with the $3.25 target price.  Although if you put it into perspective it would have been a dream for a $3.25 target price in December.  I would have never thought it was realistically possible then!

But remember:  This is just an initial estimate based upon current circumstances and conservative projections.  As things develop, the target price may be adjusted.

I think there will be many developments this year.  We have up to 3 Phase 3 trials starting for 3 different indications.  When those trials get underway, the stock will adjust.  And perhaps the target price will adjust too.

Plus, we have another analyst estimate we can point to - and that one values the company at $500M (about $5 a share).  So the average is somewhere in between.

I think the true value of the company is much higher than either estimate.  And people are starting to figure that out...

IMHO.  DYODD.  GLTA.




Bullboard Posts